Amarin Corporation PLC (NASDAQ:AMRN)
| 6.62 Data as of Jun 17 |  -0.14 / -2.07%Today’s Change | 6.25 Today|||52-Week Range 15.96 | -18.17% Year-to-Date |
Latest AMRN News | Press Releases
| AstraZeneca's Buying Spree Bolsters Pipeline Jun 14 / MotleyFool.com | A Winning Biotechnology Bet Jun 10 / MotleyFool.com |
| Amarin Stock May Be Worth the Wait Jun 12 / TheStreet.com |
Today’s Trading
| Previous close | 6.76 |
| Today’s open | 6.76 |
| Day’s range | 6.61 - 6.80 |
| Volume | 2,439,681 |
| Average volume (3 months) | 3,772,420 |
| Market cap | $1.0B |
| Dividend yield | -- |
Data as of 4:00pm ET, 06/17/2013
Growth & Valuation
| Earnings growth (last year) | -133.73% |
| Earnings growth (this year) | -58.18% |
| Earnings growth (next 5 years) | +30.70% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NKTRNektar Therapeutics | +0.06 | +0.65% |
| LXRXLexicon Pharmaceutic... | -0.04 | -1.78% |
| EXELExelixis Inc | -0.03 | -0.64% |
| NXTMNxstage Medical Inc | +0.16 | +1.13% |
Data as of 4:00pm ET, 06/17/2013
Financials
| Next reporting date | August 13, 2013 |
| EPS forecast (this quarter) | -$0.38 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$179.5M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
Executive Chairman & Chief Executive Officer Joseph S. Zakrzewski, MBA |
President & Chief Financial Officer John F. Thero, CPA |
Corporate headquarters Dublin, Dublin |
Forecasts
